ArticleCancer discovery2018
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 3 pooled it
16.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
227 citing papers in PubMed, 3 syntheses or guidelines pooled it, 365 citations in OpenAlex.
- How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer.Future oncology (London, England) · 2024Pooled it
- Pooled it
- Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Pooled it
- A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Nature medicine · 2026Trial
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.JCO precision oncology · 2025Trial
- A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Classical Subtypes.The Journal of molecular diagnostics : JMD · 2024Trial
- Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.Cancer · 2022Trial
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Cancer letters · 2021Trial
- A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Progress and challenges in expanding access to clinical trials in pancreatic cancer.Communications medicine · 2026Review
- Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling.Pharmaceutics · 2026Review
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53.The Journal of biological chemistry · 2026Article
- GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma.Cell reports · 2026Article
- Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma.NPJ precision oncology · 2026Article
- Article
- Epigenetic and transcriptional control of classical and basal-like cell states in pancreatic ductal adenocarcinoma.Gastroenterology report · 2026Review
167 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
61 authors at 11 institutions in 1 country.
Andrew J Aguirre *Dana-Farber Cancer Institute, Boston, Massachusetts. andrew_aguirre@dfci.harvard.edu carter.scott@jimmy.harvard.edu brian_wolpin@dfci.harvard.edu.
Jonathan A Nowak *Dana-Farber Cancer Institute, Boston, Massachusetts.
Nicholas D Camarda *Dana-Farber Cancer Institute, Boston, Massachusetts.
Richard A Moffitt *Department of Biomedical Informatics, Department of Pathology, Stony Brook University, Stony Brook, New York.ORCID 0000-0003-2723-5902
Arezou A GhazaniDana-Farber Cancer Institute, Boston, Massachusetts.
Mehlika Hazar-RethinamMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Srivatsan RaghavanDana-Farber Cancer Institute, Boston, Massachusetts.
Jaegil KimBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Lauren K BraisDana-Farber Cancer Institute, Boston, Massachusetts.
Dorisanne RagonDana-Farber Cancer Institute, Boston, Massachusetts.
Marisa W WelchDana-Farber Cancer Institute, Boston, Massachusetts.
Emma ReillyDana-Farber Cancer Institute, Boston, Massachusetts.
Devin McCabeDana-Farber Cancer Institute, Boston, Massachusetts.
Lori MariniDana-Farber Cancer Institute, Boston, Massachusetts.
Kristin AnderkaBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Karla HelvieDana-Farber Cancer Institute, Boston, Massachusetts.
Nelly OliverDana-Farber Cancer Institute, Boston, Massachusetts.
Ana BabicDana-Farber Cancer Institute, Boston, Massachusetts.
Annacarolina Da SilvaDana-Farber Cancer Institute, Boston, Massachusetts.
Brandon NadresMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Emily E Van SeventerMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Heather A ShahzadeMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Joseph P St PierreDana-Farber Cancer Institute, Boston, Massachusetts.
Kelly P BurkeDana-Farber Cancer Institute, Boston, Massachusetts.
Thomas ClancyDana-Farber Cancer Institute, Boston, Massachusetts.
James M ClearyDana-Farber Cancer Institute, Boston, Massachusetts.
Leona A DoyleDana-Farber Cancer Institute, Boston, Massachusetts.
Kunal JajooDana-Farber Cancer Institute, Boston, Massachusetts.
Nadine J McClearyDana-Farber Cancer Institute, Boston, Massachusetts.
Jeffrey A MeyerhardtDana-Farber Cancer Institute, Boston, Massachusetts.
Janet E MurphyMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Kimmie NgDana-Farber Cancer Institute, Boston, Massachusetts.
Anuj K PatelDana-Farber Cancer Institute, Boston, Massachusetts.
Kimberly PerezDana-Farber Cancer Institute, Boston, Massachusetts.
Michael H RosenthalDana-Farber Cancer Institute, Boston, Massachusetts.
Douglas A RubinsonDana-Farber Cancer Institute, Boston, Massachusetts.
Marvin RyouDana-Farber Cancer Institute, Boston, Massachusetts.
Geoffrey I ShapiroDana-Farber Cancer Institute, Boston, Massachusetts.
Ewa SicinskaDana-Farber Cancer Institute, Boston, Massachusetts.
Stuart G SilvermanDana-Farber Cancer Institute, Boston, Massachusetts.
Rebecca J NagyDepartment of Medical Affairs, Guardant Health, Inc., Redwood City, California.
Richard B LanmanDepartment of Medical Affairs, Guardant Health, Inc., Redwood City, California.
Deborah KnoerzerBioMed Valley Discoveries, Kansas City, Missouri.
Dean J WelschBioMed Valley Discoveries, Kansas City, Missouri.
Matthew B YurgelunDana-Farber Cancer Institute, Boston, Massachusetts.
Charles S FuchsDana-Farber Cancer Institute, Boston, Massachusetts.
Levi A GarrawayDana-Farber Cancer Institute, Boston, Massachusetts.
Gad GetzBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Jason L HornickDana-Farber Cancer Institute, Boston, Massachusetts.
Bruce E JohnsonDana-Farber Cancer Institute, Boston, Massachusetts.
Matthew H KulkeDana-Farber Cancer Institute, Boston, Massachusetts.
Robert J MayerDana-Farber Cancer Institute, Boston, Massachusetts.
Jeffrey W MillerHarvard T.H. Chan School of Public Health, Boston, Massachusetts.
Paul B ShynDana-Farber Cancer Institute, Boston, Massachusetts.
David A TuvesonCold Spring Harbor Laboratory, Cold Spring Harbor, New York; Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, New York.
Nikhil WagleDana-Farber Cancer Institute, Boston, Massachusetts.
Jen Jen YehDepartments of Surgery and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
William C HahnDana-Farber Cancer Institute, Boston, Massachusetts.
Ryan B CorcoranHarvard Medical School, Boston, Massachusetts.
Scott L CarterDana-Farber Cancer Institute, Boston, Massachusetts. andrew_aguirre@dfci.harvard.edu carter.scott@jimmy.harvard.edu brian_wolpin@dfci.harvard.edu.
Brian M WolpinDana-Farber Cancer Institute, Boston, Massachusetts. andrew_aguirre@dfci.harvard.edu carter.scott@jimmy.harvard.edu brian_wolpin@dfci.harvard.edu.
Brigham and Women's Hospital · USBroad Institute · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USHarvard University · USDiscover Vision Centers · USGuardant (United States) · USMassachusetts Department of Public Health · USCold Spring Harbor Laboratory · USStony Brook University · USUniversity of North Carolina at Chapel Hill · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MHarvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MCirculating Biomarker Consortium for Pancreatic Cancer Early DetectionU01CA210171 · NCI · DANA-FARBER CANCER INST · PI Michael H. Rosenthal, Brian Matthew Wolpin · 2016 to 2026
$8.7MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MTumor Subtypes and Therapy Response in Pancreatic CancerR01CA199064 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TSAI, SUSAN, YEH, JEN JEN · 2016 to 2021
$4.4MSystematic identification of oncogenic KRAS synthetic lethal interactionsU01CA199253 · NCI · BROAD INSTITUTE, INC. · PI HAHN, WILLIAM C. · 2015 to 2019
$3.7MSystematic interrogation of the pancreatic cancer microenvironment in patient-derived specimensU01CA224146 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2017 to 2021
$3.0MTranslating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic CancerR01CA227517 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOONG, ALBERT · 2019 to 2023
$2.3MFunctional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancerK08CA218420 · NCI · DANA-FARBER CANCER INST · PI AGUIRRE, ANDREW JAMES · 2017 to 2021
$886kNCATS NIH HHS UL1 TR001102NCI NIH HHS K08 CA218420NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA199064NCI NIH HHS R01 CA227517NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA199253NCI NIH HHS U01 CA210171NCI NIH HHS U01 CA224146
Abstract
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alterations were identified in 48% (34/71) and pathogenic/likely pathogenic germline alterations in 18% (13/71) of patients. Overall, 30% (21/71) of enrolled patients experienced a change in clinical management as a result of genomic data. Twenty-six patients had germline and/or somatic alterations in DNA-damage repair genes, and 5 additional patients had mutational signatures of homologous recombination deficiency but no identified causal genomic alteration. Two patients had oncogenic in-frame
Indexed as
Genetic VariationAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalDNA RepairExome SequencingFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksGenomicsGerm-Line MutationHomologous RecombinationHumansMale
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.